Genetic background of high myopia in children Authors: Urh Šenk, Bernard Čižman, Karin Writzl, Manca Tekavčič Pompe, Giuseppe Novelli, Giuseppe Novelli, Giuseppe Novelli Published: 2024 ABSTRACT ObjectiveHigh myopia is a significant risk factor for irreversible vision loss and can occur in isolation or as a component of various syndromes. However, the genetic basis of early-onset high myopia remains poorly understood. We aimed to identify the causative genetic variants for high myopia in a cohort of Slovenian children.MethodsThe study included children referred to a tertiary paediatric ophthalmology centre at the University Eye Clinic in Ljubljana between 2010 and 2022. The participants met the following inclusion criteria: age ≤ 15 years and high myopia ≤-5.0 D before the age of 10 years. Genetic analysis included exome sequencing and/or molecular karyotyping. Participants were categorized based on clinical presentation: high myopia with systemic involvement, high myopia with ocular involvement, and isolated high myopia.ResultsGenetic analysis of 36 probands revealed a genetic cause of high myopia in 22 (61.1%) children. Among those with systemic involvement (50.0%), genetic causes were identified in 13 out of 18 children, with Stickler’s and Pitt-Hopkins being the most common syndromes. Among cases of high myopia with ocular involvement (38.9%), a genetic cause was found in 8 out of 14 probands, including (likely) pathogenic variants in genes related to retinal dystrophies (CACNA1F, RPGR, RP2, NDP). The non-syndromic ARR3- associated high myopia was identified in the isolated high myopia group.ConclusionsA genetic cause of high myopia was identified in 61.1% of children tested, demonstrating the value of genetic testing in this population for diagnosis and proactive counseling. Introduction Myopia is one of the most common refractive errors, in which images of distant objects are focused in front of the retina, resulting in blurred distance vision [1, 2]. Myopia can be categorised as mild (-0.5 D to -3.00 D), moderate (-3.00 D to -5.00 D or -6.00 D), or high (≤ -5.00 D or -6.00 D) [1]. Some sources also define high myopia (HM) based on an axial length > 26 mm [3, 4]. This classification has clinical significance, as individuals with high myopia face a substantially increased risk of secondary ocular pathologies and irreversible vision loss. Pathologic myopia is a distinct type of HM characterized by degenerative ocular tissue damage associated with myopic maculopathy, retinoschisis, and other complications [1, 2]. Although myopia is often considered a benign condition, it is a major public health problem [2]. Projections show that by 2050, one in two people will be myopic, and one in ten will be highly myopic [5]. While common myopia was once considered primarily genetic, it is now understood as a complex condition arising from the interplay of environmental and genetic factors, with individual genes influencing the severity of the clinical presentation [2, 6]. The familial clustering of myopia, particularly among offspring of myopic parents, highlights the importance of genetic factors in its development. The influence of the genome on the development of the eye, including myopia susceptibility, has also been demonstrated in several twin studies [7]. The stronger familial clustering observed in HM in contrast to low myopia indicates a greater genetic influence on the development of HM [8]. Today, more than 100 different genes and over 20 chromosomal loci are associated with the development of myopia [4]. Some HM cases demonstrate monogenic inheritance, with alterations in a single gene (e.g., ARR3, BSG, CTSH, CCDC111, LEPREL1, LOXL3, LRPAP1, NDUFAF7, P4HA2, SCO2, SLC39A5, UNC5D and ZNF644) as the primary cause [1]. Isolated alterations in a single causative gene may also be responsible for many cases of syndromic (high) myopia (i.e., myopia that occurs in association with a specific systemic disability or in combination with at least one other condition). These conditions include a number of intellectual disability syndromes (e.g., Angelman, Bardet-Biedl, Cohen, and Pitt-Hopkins syndromes) and inherited connective tissue disorders such as Marfan, Stickler and some forms of Ehlers-Danlos syndrome [1, 6, 9]. The classification into syndromic and non-syndromic myopia can sometimes be unclear, especially in patients with a syndrome in which the clinical manifestation is limited exclusively to an isolated HM, without additional systemic or ocular features, as occasionally observed in Stickler syndrome, for example [10]. For this reason, a phenotype-based classification of HM into the following groups, used in similar studies, may enhance clinical decision-making: HM with systemic features, HM with ocular involvement, and isolated HM [6, 10]. Recent advances in genetics and genetic testing have enabled the investigation of the genetic background of HM in children in Slovenia, with the potential for improved diagnosis and future therapies. This study aimed to identify the causative genetic alterations (chromosomal rearrangements, point mutations, insertions, deletions, duplications, …) that suggest a high causative probability for HM in Slovenian children aged 15 years or younger using exome sequencing (ES) and molecular karyotyping. Additionaly, it seeks to determine whether routine genetic testing in the studied population is justified. Materials and methods The cohort We used data from children referred to the tertiary pediatric ophthalmology center at University Eye Clinic in Ljubljana between 2010 and 2022 who met the following inclusion criteria: age up to and including 15 years and HM equal to or exceeding SE -5.0 D before the age of 10 years. We excluded children who were highly likely to have developed HM as a result of another eye condition, e.g., retinopathy of prematurity, congenital glaucoma, secondary glaucoma after early surgery for congenital cataract, other types of secondary glaucoma, and exacerbation or development of HM as a complication of surgical treatment of other ocular pathology. Children with HM who underwent genetic analysis as part of segregation analysis but were not the probands were excluded. A flowchart of children who participated in the study is presented in Fig 1. The flowchart outlining participant enrollment, exclusion, and attrition. Written informed consent was obtained from the parents of all participating children. The research adhered to the tenets of the Declaration of Helsinki and was approved by the Republic of Slovenia National Medical Ethics Committee (case number 0120-284/2022/3). Genetic testing The results of the genetic tests were reviewed at the Clinical Institute of Genomic Medicine (CIGM) and the Genetic Clinic of the Children’s Clinic in Ljubljana. Patients with non-syndromic high myopia (HM) underwent exome sequencing (ES). In syndromic HM cases, molecular karyotyping was performed first, with ES used subsequently if no causative mutation was identified. All genetic testing was performed as part of routine diagnostics. The DNA was isolated from peripheral blood samples using the Qiagen Mini kit (Qiagen, Valencia, CA). Microarray analysis was performed using the oligonucleotide array Agilent Technologies 4 × 180 K, according to the manufacturer’s instructions. The array images were acquired using the Agilent laser scanner G2565CA. The image files were quantified using the Agilent Feature extraction software and analyzed with the Agilent Cytogenomics 5.3 software (Agilent Technologies). Interpretation of the microarray results was performed according to the ACMG and ClinGen guidelines [11], taking into account publicly available databases (DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources https://decipher.sanger.ac.uk/), Database of Genomic Variants (DGV) (http://dgv.tcag.ca/dgv/app/home), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), ClinGen (http://dbsearch.clinicalgenome.org/search/)), and the in-house database of detected variants [12]. Exome sequencing was performed using a standardized series of procedures, starting with an in-solution capture of exome sequences (TruSight One, TruSight Exome, and Nextera Coding Exome capture kits, Agilent SureSelect Human All Exon v2, Agilent SureSelect Human All Exon v5 capture kits). This was followed by sequencing on Illumina MiSeq or Illumina HiSeq 2500 platform. Exome data analysis was conducted using an internally developed pipeline along with various bioinformatics approaches, including phenotype-driven gene targets and trio design, as previously described [13, 14]. Briefly, each variant was annotated based on data such as chromosomal location, zygosity, transcript information, predicted effects on protein structure and function, and local and global frequency data from The Genome Aggregation Database (gnomAD) and the Slovenian Genomic Database. In silico predictions and previous associations with diseases were sourced from the HGMD, LOVD, and ClinVar databases, as well as through literature searches. Variants were categorized as pathogenic, likely pathogenic, or variant of uncertain significance according to the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology standards for interpreting sequence variants [15]. Variants classified as pathogenic or likely pathogenic were labeled causative if they were associated with patient phenotypes. In patients with isolated HM and those with HM and other ocular involvement, an eye disorder gene panel comprising 549 genes was used (S1 Table). For patients with HM and systemic involvement, this panel was supplemented with a phenotype-based gene panel generated using a web tool (https://www.kigm.eu/generator/). This tool facilitated tracking genes associated with clinical signs and symptoms using HPO nomenclature [13, 14]. If results were negative, an untargeted interpretation of all exome variants was performed. Phenotyping The children were examined by a pediatric ophthalmologist and a clinical geneticist and categorized into three groups based on their clinical presentation: HM with systemic involvement, HM with other ocular involvement, and isolated HM. Children with HM and systemic features with or without additional ocular pathologies were classified in HM with systemic involvement group, while the HM with other ocular involvement group included children in which HM was accompanied with additional pathologies limited to the eye (e.g., retinal dystrophies, strabysmus, anisometric amblyopia, nystagmus, …). Statistics Thirty-seven children who underwent genetic testing were included in the analysis. Demographic data (age and sex) and refractive error are presented as average value ± standard deviation (SD). Basic calculation software was used to perform statistical analysis. Statistical calculations were based on 36 probands, as two children were siblings sharing the same genetic variant. The cohort was divided into four groups based on the result of the genetic testing: those with confirmed genetic causes for HM, those with variants of uncertain significance (VUS), those with (likely) pathogenic genetic variants related to a syndromic phenotype but not previously linked to HM development, and those lacking identifiable genetic variants to explain their clinical phenotype. Percentages of genetically confirmed probands were calculated and presented, divided in systemic, ocular involvement and isolated high myopia group. Results A total of 46 children (24 boys and 22 girls) were included in the study. The mean age of the children at inclusion in the study was 8.9 ± 3.7 years, and the mean refractive error was -9.1 ± 3.1 D. Nine children were lost to follow-up due to unavailability, non-consent to genetic testing, or incomplete genetic analysis. Of the 36 probands, we confirmed a genetic cause of HM in 22 children (61.1%). Two children (5.6%) were found to have genetic variants classified as VUS, and four children (11.1%) had pathogenic or likely pathogenic variants in genes not previously associated with the development of myopia. In eight children (22.2%), we could not identify causative genetic variants for the distinct clinical phenotype. Table 1 shows the numerical overview of genetic testing for children in each group. Detailed information regarding clinical presentation and genetic testing for individual children can be found in Table 2. 10.1371/journal.pone.0313121.t001Table 1Numerical overview of genetic test results for all probands and their further subdivision according to subgroup.Number of probands (%)Confirmed genetic cause of HM (%)VUS (%)Other genetic variant not associated with the development of HM (%)No genetic variant to explain the clinical phenotype (%) Total sample 36 (100%)22 (61.1%)2 (5.6%)4 (11.1%)8 (22.2%) HM with systemic involvement 18 (50.0%)13 (36.1%)1 (2.8%)4 (11.1%)0 (0.0%) HM with ocular involvement 14 (38.9%)8 (22.2%)1 (2.8%)0 (0.0%)5 (13.9%) Isolated HM 4 (11.1%)1 (2.8%)0 (0.0%)0 (0.0%)3 (8.3%)VUS—variant of uncertain significance, HM—high myopia Numerical overview of genetic test results for all probands and their further subdivision according to subgroup. VUS—variant of uncertain significance, HM—high myopia 10.1371/journal.pone.0313121.t002Table 2Detailed ophthalmologic characteristics and genetic testing results in our cohort.Age (years)Refractive error (D)Signs of pathological myopiaGenetic variantType of zygosityACMG classificationDiagnosis15,7R: -1,00/30° L: -8,50-1,50/140°Peripapillary atrophy, signs of retinal thinning and eyeball elongation, L macula without reflectionarr[GRCh37] 9p24.3p24.2(2076268_2737525)x3 mat, 16p13.2(8768819_9598226)×3∼4HeterozygoteVUS/28,6RL: -8,50-1,50/180°Papillae with hypoplastic ring, thin retinal vasculature, pigment dispersion, dystrophic fundusNM_004333.4(BRAF): c.1502A>G p.(Glu501Gly)HeterozygoteLikely pathogenicNoonan syndrome35,4RL: -8,00Peripapillary atrophy, retinal thinningNM_021625.5(TRPV4): c.805C>T p.(Arg269Cys)HeterozygotePathogenicaCongenital distal spinal muscular atrophy44,8R: -7,00Rarefied pigmenttrisomy chromosome 21/PathogenicDown’s syndromeL: -6,0054,1RL: -13,00R: Retinal thinning;NM_130444.3(COL18A1): c.2174-2A>GCompound heterozygoteLikely pathogenicKnobloch syndromeL: Fundus fully hypopigmentedNM_130444.3(COL18A1): c.4759_4760delCT p.Leu1587fsPathogenic69,4R: -7,00-0,75/180°Peripapillary atrophyNM_001270399.1(TUBA1A): c.641G>A p.(Arg214His)HeterozygoteLikely pathogenicaTUBA1A tubulinopathyL: -7,00-1,50/180°79,0R: -11,25-1,5/46°Thinned chorioretina Temporal zone without vascularisationNM_016038.2(SBDS): c.183_184delinsCT (p.Lys62*), c.258+2T>CCompound heterozygotePathogenicaShwachman-Diamond syndromeL: -10,25-1,5/154°89,2RL: -14,00Peripapillary atrophy, retinal pigmentationarr[GRCh37] 18q21(47,782,339-60,231,879)x1HeterozygotePathogenicPitt-Hopkins syndrome910,8R: -10,00/NM_000138.4(FBN1): c.1481G>T p.(Cys494Phe)HeterozygoteLikely pathogenicMarfan syndromeL: -7,001011,1RL: -6,00/NM_017739.4(POMGnT1): c.1285-2A>G, c.1539+1G>ACompound heterozygotePathogenicMuscle-eye-brain disease1111,3RL: -6,00Peripapillary atrophy, retinal thinningarr[GRCh19] 8q13.2.q13.3(68,109,818-71,102,561)x1HeterozygotePathogenic8q13 microdeletion syndrome127,2RL: -9,00Peripapillary atrophy, posterior staphylomaarr[hg19] 18q21.1.q22.3(52,932,969-68,873,702)x1HeterozygotePathogenic18q deletion syndrome (includes TCF4)136,3RL: -10,00/NM_017780.3(CHD7): c.4353+1G>AHeterozygotePathogenicCHARGE syndrome1413,2R: -10,75-6/25°Retinal thinningNM_001083962.1(TCF4): c.1832T>G p.(Leu611Arg)HeterozygoteLikely pathogenicPitt-Hopkins syndromeL: -12,75-4,75/160°155,5R: -6,50-2,50/180°/NM_001348729.2(KIDINS220): c.4056+1G>THeterozygoteLikely pathogenicaSpastic paraplegia-intellectual disability-nystagmus-obesity syndromeL: -7,00-2,00/180°1612,8R: -13,50Bilateral retinal detachment (R in 2020, L in 2017))NM_149162.2(COL2A1): c.2503C>T p.(Arg835Cys)HeterozygotePathogenicStickler syndromeL: -10,001710,0R: -6,00-1,50/30°/NM_001844.5(COL2A1): c.2111dupC p.(Gly705fs)HeterozygoteLikely pathogenicStickler syndromeL: -5,50-1,50/120°1813,2R: -5,50-1,50/180°/rsa 15q11.2(Me028)x1 Methylation pattern: paternal allele absentHeterozygotePathogenicPrader-Willi syndromeL: -4,50-1,50/180°1911,2R: -15,75-1,00/90°Peripapillary atrophyNM_001852.4(COL9A2): c.803G>A p.(Gly268Asp)HeterozygoteVUS/L: -8,50-0,75/90°200,4RL: -7Thinned retinaNM_001844.5(COL2A1): c.3706delC p.(Leu1236CysfsTer13)HeterozygotePathogenicStickler syndrome219,1R: -6,50-3,50/4°/NM_001174096.1(ZEB1):c.238A>T p.(Lys80*)HeterozygoteLikely pathogenicCorneal dystrophyL: -8.00-2,50/178°225,2R: -13,00-2,0/160°Peripapillary atrophy, retinal thinningNM_001034853.2(RPGR):c.2236_2237delGA p.(Glu746fs)HemizygotePathogenicRetinal dystrophyL: -12,50-2,0/160°2314,8R:-5,75-3,50/10°Bilateral peripapillary atrophyExome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -5,00-2,50/176°248,5R: -14,75-2,25/10°Peripapillary atrophy, thinned and dystrophic chorioretinasNM_001256789.3c(CACNA1F):c.5446C>T p.(Arg1816Ter)HemizygotePathogenicDystrophy of the rods and conesL: -14,25-1,25/150°257,8R: -10,00Retinal thinningNM_000266.3(NDP):c.414C>T p.(Ala105Val)HemizygotePathogenicNorrie’s diseaseL: -12,00268,9R: -10,00-1,50/10°/NM_001034853.2(RPGR):c.2977G>T p.(Glu993*)HeterozygoteLikely pathogenicRetinal dystrophyL: -9,50-1,50/170°2712,1R: -7,00-2,50/10°Retinal thinningNM_006915.2(RP2): c.358C>T p.(Arg120Ter)HemizygotePathogenicRetinal dystrophyL: -6,50-3,0/5°2814,8R: -17,25-1,75/30°Postoperative retinal detachment L, peripapillary atrophy, retinal thinningExome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L:-16,00-2,25/80°2913,4R: -6,00/Exome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -8,003011,3R: -9,00-2,75/5°Peripapillary atrophyNM_005183.2(CACNA1F):c.448G>C p.(Gly150Arg)HemizygotePathogenicIncomplete congenital stationary night blindnessL: -9,25-3,25/160°313,9R: -7,00-1,00/80°/Exome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -7,00-1,00/18°3211,3R: -9,0Retina of rarefied pigmented appearance, papillae pale, hypoplasticExome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -7,0-2,0/90°33b4,8R: -9,00-2,0/1°/NM_004312.3(ARR3):c.214C>T p.(Arg72*)HeterozygotePathogenicX-linked myopia type 26L: -10,00-0,75/28°34b7,3R: -8,0-2,0/5°,/NM_004312.3(ARR3):c.214C>T p.(Arg72*)HeterozygotePathogenicX-linked myopia type 26L: -8,0-2,0/180°353,6R: -7,50-2,00/120°Retinal thinningExome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -7,00-1,00/120°364,9R: -14,00Retinal thinningExome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -15,003714,3R: -7,00-1,00/40°/Exome sequencing did not reveal the presence of genetic variants that could explain the clinical picture.///L: -4,00Children are classified into groups based on clinical presentation. White coloured cells represent HM with systemic features, blue colour corresponds to HM with ocular involvement and grey colour to isolated HM. D—dioptre, R—right eye, L—left eye, RL—right and left eyea variant not associated with the development of HMb from same family Detailed ophthalmologic characteristics and genetic testing results in our cohort. Children are classified into groups based on clinical presentation. White coloured cells represent HM with systemic features, blue colour corresponds to HM with ocular involvement and grey colour to isolated HM. D—dioptre, R—right eye, L—left eye, RL—right and left eye a variant not associated with the development of HM b from same family We identified a genetic cause in 13 of 18 probands with a clinical picture of HM in the context of systemic involvement. A monogenic cause was identified in eight of these children and a chromosomal cause in five. Stickler syndrome (N = 2; causative variant in the COL2A1 gene) and Pitt-Hopkins syndrome (N = 3; one causative variant in the TCF4 gene, two cases associated with 18q deletion syndrome) were most common in this cohort. In our sample, we also associated one case each of Noonan syndrome (causative variant in the BRAF gene), Knobloch syndrome (causative variants in the COL18A1 gene), Marfan syndrome (causative variant in the FBN1 gene), MEB disease (causative variants in the POMGNT1 gene), CHARGE syndrome (causative variant in the CHD7 gene), Down syndrome (trisomy 21), Prader-Willi syndrome (microdeletion of the 15q11.2 region), and 8q13 microdeletion syndrome. In one (1/18) child, we found genetic variants defined as VUS, and in four (4/18) children, we found (likely) pathogenic variants in the genes TRPV4, TUBA1A, SBDS, KIDINS220, which have not been previously associated with the development of myopia. Fourteen probands (38.9%) had a clinical presentation of HM with ocular involvement, with a monogenic cause identified in 8 of the 14 cases. Specifically, HM was identified in six children with retinal dystrophies (RPGR; N = 2, CACNA1F; N = 2, RP2, NDP) and one child each of corneal dystrophy (ZEB1) and Stickler syndrome (causative variant in the COL9A2 gene). In the group of probands with isolated HM (N = 4; 11.1%), we identified a genetic cause in one out of four probands. Specifically, a pathogenic variant in ARR3 was found in two siblings. Discussion The genetic analysis of the 36 probands revealed a genetic background for the clinical picture of HM in 61.1% of the children. HM manifested with systemic features in 50.0% of probands, with ocular involvement in 38.9%, and as an isolated disease in 11.1%. Diagnostic yield of the study The diagnostic yield of our study was higher than expected at 61.1%. Similar studies in this field report a proportion of genetically confirmed HM cases of around 20% and up to 80% in the case of specific subject selection [10, 16–19]. The high diagnostic yield of our study is most likely due to the sample selection. Namely, we included children with HM who were treated in a tertiary paediatric ophthalmology centre, so a higher proportion of pathological conditions can be expected than in the general population of children of the same age. As a result, it is difficult to extrapolate the results of the survey to the general population of children in Slovenia. This suggests that the proportion of genetically explainable cases of HM in children is probably lower in the general population. However, given the high diagnostic yield, it can be argued that referral of children with HM treated in tertiary-level ophthalmology outpatient clinics for genetic testing is reasonable, as this is likely to clarify the aetiology of their clinical condition. HM with systemic involvement and HM with other ocular involvement The percentage of participants in groups with systemic involvement or with ocular involvement varies widely between studies. While Marr et al. (2001) reported 92% of HM cases associated with systemic or ocular features, the hospital-based sampling limits the study’s generalizability [20]. In contrast, other investigators have reported a significantly lower percentage of HM cases with systemic or ocular involvement, ranging from 27% to 44% [10, 21]. In particular, Marfan syndrome and Stickler syndrome, in which HM is a common clinical manifestation, occurred frequently in this group. Notably, the potential for Stickler syndrome to initially present as isolated HM highlights the difficulty of phenotypic classification, as other ocular features may manifest later [22]. In our study, 50% of children had HM with systemic involvement, which is significantly higher than the 15% reported by Haarman et al. [10]. The high proportion of systemic disabilities in our sample reflects the elevated prevalence of these conditions among children treated in an at-risk outpatient clinic. On the other hand, our result is very similar to that of Marr J.E. et al., who found 54% of participants to have an underlying systemic disease with or without other eye problems [20]. In the same study, a similar percentage was found to have HM with other eye problems (e.g., lens subluxation, coloboma, retinal dystrophy, anisometropic amblyopia), namely 38% compared to 38.9% in our study. Among the syndromes in which HM is common, Stickler’s and Knobloch’s syndromes are the most frequently described in the literature, which is also consistent with the results of our study [10, 17, 18]. In our sample, we also found HM associated with several other syndromes, and it is particularly interesting that, in contrast to the aforementioned studies, we reported three children (13.6% of genetically confirmed HM cases) with Pitt-Hopkins syndrome. It is also worth noting that our study describes cases of HM in individuals with variants in genes that have not yet been clearly associated with the development of myopia (TRPV4, TUBA1A, SBDS, KIDINS220). The TRPV4 gene encodes for a transient receptor potential (TRP) channel that is expressed in all ocular tissues and is critical for maintaining proper ocular physiology. Disturbances in its expression are mainly associated with skeletal dysplasia and neuromuscular disorders, such as congenital distal spinal muscular atrophy, which was the main phenotype of the proband 3, in addition to HM. While myopia has not been previously reported in individuals with TRPV4-related disorders, its potential role in the development of eye diseases such as glaucoma and retinopathy has already been described [23]. TUBA1A encodes for α-tubulin, a major component of microtubules, which are involved in essential cellular processes of intracellular transport, cell division and neuronal migration. Pathogenic variants in TUBA1A have been shown to cause a neurodevelopmental syndrome, characterized by structural brain malformations, congenital microcephaly, developmental delay, intellectual disability, and epilepsy (OMIM: 611603) [24]. Proband 6 carries a de novo heterzygous pathogenic variant c.641G>A, p.(Arg214His) in TUBA1A. Her phenotype includes hypotonia, severe global developmental delay, intellectual disability, epileptic encephalopathy, acquired microcephaly, and HM. Tubulin-related genes are essential for brain and eye development. TUBA1A is expressed in the developing eye and has been shown to be essential for the optic nerve regeneration in the zebrafish model [25]. Patients with pathogenic TUBA1A variants and various eye anomalies such as coloboma (PMID: 26130693, PMID: 38502138), microphthalmia and cataracts (PMID: 26294046) have been reported, demonstrating the importance of this gene in eye development, structure and function [26–28]. The KIDINS220 gene encodes a scaffolding transmembrane protein that controls neuronal cell survival, differentiation into exons and dendrites, and synaptic plasticity. De novo loss-of-function variants involving the last 2 exons (29 and 30) of KIDINS220 have been associated with spastic paraplegia, intellectual disability, nystagmus, and obesity (SINO) (OMIM #617296) [29]. The phenotype of the proband 15 in our study with the de novo likely pathogenic variant (c.4053+1G>T) corresponded to SINO syndrome, and the ocular symptoms included nystagmus, strabismus, amblyopia, high myopia, and astigmatism. Interestingly, a similar ophthalmologic phenotype was also observed in her identical twin sister with SINO syndrome, who did not participate in the study because her myopia was below the threshold for inclusion in the study. Expression studies during zebrafish and Xenopus laevis embryogenesis have demonstrated dynamic expression of KIDINS220 in the eye region. Additionally, ophthalmologic phenotypes, including nystagmus, reduced vision, and often esotropia, possibly secondary to hypermetropia, have already been described in individuals with SINO syndrome, indicating a role for the gene in eye function [29]. Although pathogenic variants in the KIDINS220 have not yet been linked to the development of myopia and therefore cannot be considered causative for this phenotype, the number of individuals SINO syndrome is still small, suggesting that the complete spectrum of ophthalmologic phenotypes may not yet be fully understood. In the group with only ocular involvement, we observed 6 cases of (probably) pathogenic variants in genes associated with retinal dystrophies (RPGR; N = 2, CACNA1F; N = 2, RP2, NDP), which corresponds to 27.3% of all genetically confirmed cases of HM. This is a lower but comparable proportion to the study by Haarman et al. in which pathogenic variants in genes associated with retinal dystrophies were found in 39% of genetically confirmed HM cases (FAM161A, GUCY2D, PDE6H, CACNA1F, NYX, RPGR and TRPM1) [10]. A novel pathogenic NDP variant was identified in a patient with Norrie’s disease. However, a variant affecting the same amino acid site but replacing it with a different amino acid has been previously reported in a patient with Norrie’s disease [30]. The RP2 variant found is the most frequently reported pathogenic variant in the RP2 gene in patients with X-linked retinitis pigmentosa [31, 32]. Causal alterations in the CACNA1F gene are responsible for incomplete congenital stationary night blindness 2A (OMIM #300071) and retinal dystrophy (OMIM #300476). Both variants found in our study have already been described in the literature [33, 34]. Pathogenic variants in the RPGR gene are a known cause of X-linked retinal dystrophy in male patients, which also includes X-linked cone and rod dystrophy 1 (OMIM #304020) and retinitis pigmentosa 3 (OMIM #300029). In addition, we identified a pathogenic heterozygous variant in the ZEB1 gene that is a known cause of posterior polymorphous corneal dystrophy 3 (OMIM #609141) and Fuchs endothelial corneal dystrophy 6 (OMIM #613270). Isolated form of HM Our finding of a low prevalence of isolated high myopia (HM) aligns with the 8% reported by Marr et al. [20]. They concluded that the diagnosis of isolated HM can only be made by a process of elimination and that in the case of apparently isolated HM in the first 10 years of life, possible systemic disease should be considered rather than isolated HM, given the significantly higher incidence of ocular and systemic abnormalities associated with HM [20]. We identified a pathogenic variant in the ARR3 gene occurring in female siblings, a variant previously reported in female myopia patients in two large families [35–37]. Mutations in ARR3 are recognized as a common cause of isolated HM with X-linked inheritance and female-restricted HM [10, 18]. Strengths, limitations, and relevance of the study The study’s limited sample size, selective participant recruitment, and short duration necessitate cautious interpretation of findings, particularly regarding broader epidemiological implications. A large-scale, national study is needed to obtain a more accurate picture of HM genetic background in the Slovenian pediatric population. This study should include a broader spectrum of children with HM and reduce potential sampling biases seen in our tertiary-care setting. Conclusions Our study employed molecular karyotyping and exome sequencing to investigate the genetic basis of HM in children aged 15 years or younger. We identified genetic causes for HM in a significant proportion of children. The diagnostic yield (61.1%) exceeded initial expectations but likely reflects the study’s focus on patients from a tertiary care setting. Nevertheless, the high diagnostic performance suggests that genetic testing in children with myopia treated in specialised clinics may be important to identify the underlying genetic aetiology, as HM may be the first indication of a more complex disorder (e.g., Stickler’s or Marfan syndrome). Overall, our findings advance the understanding of the genetic background of HM, highlighting the value of genetic testing for diagnosis, counseling, and potential preventive interventions. Supporting information Eye disorder gene panel. (DOCX) 5 May 2024 Submitted filename: Cover letter 2.docx 28 Jun 2024 PONE-D-24-12970Genetic background of high myopia in childrenPLOS ONE Dear Dr. Tekavčič Pompe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please edit the manuscript as suggested by the reviewers in a precise and accurate manner which is then reported in the response letter point by point.Please ensure that your decision is justified on PLOS ONE’s publication criteria and not, for example, on novelty or perceived impact. For Lab, Study and Registered Report Protocols: These article types are not expected to include results but may include pilot data. ============================== Please submit your revised manuscript by Aug 12 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Giuseppe Novelli Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript was presented as a "research article" although it lacked some objectives such as a description of the procedures, the information used to obtain the results and the implications of the results produced. The introduction gives a fair overview of high myopia. The objective of the manuscript is not clear, therefore it is recommended to describe it in more detail. In the "Genetic Testing" section, it is recommended to include details of the biological source used for the DNA extraction and molecular experiments as well as notes on ES and molecular karyotyping protocols. Were virtual panels used in the analysis of ES data? If yes, a list of genes should be provided. It is also important to clarify the workflow used for data analysis. In the "Statistics" section, the authors must describe the methods used and the use of any calculation software if it has been employed. The authors need to clarify whether the syndromic status of the patients was highlighted beforehand. This is a crucial point in defining the objectives of the paper. In the discussion, the part describing "new" genes must be supported by specific clinical evidence that can exclude/include the presence of disease phenotypes. These data are crucial for the clarification of the relationship between high myopia and the different variants identified. Reviewer #2: The authors present an interesting genetic study in myopic young patients. Some comments are reported below: 1. This part should be removed from the statistic paragraph: "A total of 46 children (24 boys and 22 girls) were included in the study. The mean age of the children 119 at inclusion in the study was 8.9 ± 3.7 years, and the mean refractive error was -9.1 ± 3.1 D. Nine 120 children were lost to follow-up due to unavailability, non-consent to genetic testing, or incomplete 121 genetic analysis." And included in the results paragraph. There is no statistical analysis reported in this study and no statistical tests have been reported but simply the results of the study have been reported. Lisa ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 19 Sep 2024 We are writing to resubmit a revised manuscript titled “Genetic background of high myopia in children” for publication in PLOS ONE. Reviewers' valuable comments and suggestions are greatly appreciated and have undoubtedly improved the quality of our work. In response to the reviewers' feedback, we have prepared a detailed table addressing each comment and outlining the specific changes made in the manuscript. Additionally, we have made specific revisions directly in the text of the manuscript, which we have also attached. We are confident that these revisions have strengthened our manuscript and we look forward to your feedback. Thank you for your time and consideration. Reviewers' comments and author's response (R) Reviewer 1: “ The manuscript was presented as a "research article" although it lacked some objectives such as a description of the procedures, the information used to obtain the results and the implications of the results produced. The introduction gives a fair overview of high myopia.” R: As suggested the description of the procedures was provided in more comprehensive way, we additionally specified the sources and nature of the information used to obtain our results and expanded our discussion on the implications of the results. The "Genetic Testing" section has been rewritten in a more detailed and comprehensive manner. Reviewer 1: “The objective of the manuscript is not clear, therefore it is recommended to describe it in more detail.” R: As suggested the objective of the manuscript was made more comprehensive: “This study aimed to identify the genetic alterations (chromosomal rearrangements, point mutations, insertions and deletions, duplications, …) that suggest a high causative probability for HM in Slovenian children aged 15 years or younger using exome sequencing (ES) and molecular karyotyping.” Reviewer 1: “In the "Genetic Testing" section, it is recommended to include details of the biological source used for the DNA extraction and molecular experiments as well as notes on ES and molecular karyotyping protocols. Were virtual panels used in the analysis of ES data? If yes, a list of genes should be provided.” R: We have revised our work to include a more detailed description of the genetic protocols and methods used. The "Genetic Testing" section has been rewritten in a more detailed and comprehensive manner. Reviewer 1: “It is also important to clarify the workflow used for data analysis.” R: Workflow used for data analysis was presented more clearly with a flow-chart, that was already added as a separate file. Reviewer 1: “In the "Statistics" section, the authors must describe the methods used and the use of any calculation software if it has been employed.” R: We have updated the "Statistics" section to include a more detailed description, in order to reflect our approach and provide more clarity: “Demographic data (age and sex) as well as refractive error are shown as average value ± standard deviation (SD). Basic calculation software was used for numerical/statistical analysis.Percentages of genetically confirmed probands were calculated and presented, divided in systemic, ocular involvement and isolated high myopia group.” Due to the nature and design of our research, performing statistical tests beyond the description of demographic data was not deemed appropriate or meaningful. Reviewer 1: “The authors need to clarify whether the syndromic status of the patients was highlighted beforehand.” R: The syndromic status of the patients was determined based on data available in the databases at the time of data capture, the most recent ophthalmological examination results and the latest genetic testing results. As noted, the classification into syndromic and non-syndromic myopia can sometimes be ambiguous, particularly in cases where a syndrome manifests solely as isolated HM without additional systemic or ocular features, as occasionally observed for example in Stickler syndrome. For this reason, a phenotype-based classification of HM into the following groups, used in similar studies was also utilized in our study: HM with systemic features, HM with ocular involvement, and isolated HM. Unfortunately we did not have access to data regarding the exact dates when the syndrome diagnoses were confirmed in specific cases. Reviewer 1: “In the discussion, the part describing "new" genes must be supported by specific clinical evidence that can exclude/include the presence of disease phenotypes. These data are crucial for the clarification of the relationship between high myopia and the different variants identified.” R: We have provided a more detailed and clinical evidence-supported discussion regarding "new" genes. Reviewer 2: “This part should be removed from the statistic paragraph: "A total of 46 children (24 boys and 22 girls) were included in the study. The mean age of the children at inclusion in the study was 8.9 ± 3.7 years, and the mean refractive error was -9.1 ± 3.1 D. Nine children were lost to follow-up due to unavailability, non-consent to genetic testing, or incomplete genetic analysis." And included in the results paragraph.” R: The suggested corrections have been made: the specified section has been removed from the statistics paragraph and included in the results paragraph. Reviewer 2: “There is no statistical analysis reported in this study and no statistical tests have been reported but simply the results of the study have been reported.” R: We have revised the "Statistics" section to provide more specific details about demographic data and calculation. Reviewer 2: Have the authors made all data underlying the findings in their manuscript fully available? R: All data underlying and supporting the findings can be found in the table included in the manuscript file. Data regarding the genetic alterations and variants was retrieved from the genetic testing reports we accessed at the Clinical Institute of Genomic Medicine’s database in Ljubljana. Reviewer 2: Improvement of technical aspects of the manuscript R: We have improved the technical aspects of the manuscript by reorganizing the Methods and Statistics sections, enhancing the presentation of confirmed cases in the table, and adding specific minor corrections. Data policy The data that support the findings of this study are shown in the manuscript. The genetic raw data are not publicly available due to privacy and ethical restrictions. Reviewer:Is the manuscript presented in an intelligible fashion and written in standard English? R: Slight improvements in wording were made to make the manuscript more comprehensible. Proofreading of the manuscript was performed by a native English speaker, proficient in proofreading of medical papers. Submitted filename: Response to Reviewers.docx 21 Oct 2024 Genetic background of high myopia in children PONE-D-24-12970R1 Dear Dr. Manca Tekavčič Pompe, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Giuseppe Novelli Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 24 Oct 2024 PONE-D-24-12970R1 PLOS ONE Dear Dr. Tekavčič Pompe, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Prof. Giuseppe Novelli Academic Editor PLOS ONE